GE collaborates with Sloan-Kettering for colon cancer diagnosis
GE Global Research has launched a study with Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City to better understand the early stages of colon cancer which will improve treatment selection and outcomes for cancer patients in the future.

New molecular analysis from GE’s cancer mapping technology has the potential to identify early-stage cancer patients at higher risk for re-occurrence, said GE. As part of the study, GE and MSKCC will collaborate to evaluate biomarkers for their prognostic value to segregate high-risk from low-risk early stage colon cancers.

Scientists and investigators from GE and MSKCC will work together to first identify cancer cases, acquire and process cancer tissues, and collect treatment outcome information, then biochemically and statistically analyze the molecular profiles for the cancer tissues, and relate the molecular profiles to treatment outcomes, said GE Global Research located in Niskayuna, New York.